Crossref
EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges
AME Clinical Trials Review · 2023
DOI: 10.21037/actr-23-30 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Mingjia Li und 2 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, M., Owen, D. H., & Otterson, G. A. (2023). EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-30
Vancouver
Li M, Owen DH, Otterson GA. EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-30
BibTeX
@article{Li2023,
author = {Li, Mingjia and Owen, Dwight H. and Otterson, Gregory A.},
title = {EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges},
journal = {AME Clinical Trials Review},
year = {2023},
doi = {10.21037/actr-23-30}
}
EUVIMED